GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $794.77 million. The enterprise value is $1.08 billion.
| Market Cap | 794.77M |
| Enterprise Value | 1.08B |
Important Dates
The next confirmed earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 342.57 million shares outstanding. The number of shares has decreased by -8.98% in one year.
| Current Share Class | 108.61M |
| Shares Outstanding | 342.57M |
| Shares Change (YoY) | -8.98% |
| Shares Change (QoQ) | -2.03% |
| Owned by Insiders (%) | 3.94% |
| Owned by Institutions (%) | 18.41% |
| Float | 95.34M |
Valuation Ratios
The trailing PE ratio is 27.16 and the forward PE ratio is 25.49.
| PE Ratio | 27.16 |
| Forward PE | 25.49 |
| PS Ratio | 1.00 |
| Forward PS | 1.02 |
| PB Ratio | 1.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.83 |
| P/OCF Ratio | 4.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.80, with an EV/FCF ratio of 6.54.
| EV / Earnings | 35.34 |
| EV / Sales | 1.35 |
| EV / EBITDA | 8.80 |
| EV / EBIT | 10.13 |
| EV / FCF | 6.54 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.88.
| Current Ratio | 2.61 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | 4.16 |
| Debt / FCF | 3.30 |
| Interest Coverage | 2.49 |
Financial Efficiency
Return on equity (ROE) is 4.54% and return on invested capital (ROIC) is 6.46%.
| Return on Equity (ROE) | 4.54% |
| Return on Assets (ROA) | 4.75% |
| Return on Invested Capital (ROIC) | 6.46% |
| Return on Capital Employed (ROCE) | 9.17% |
| Weighted Average Cost of Capital (WACC) | 9.04% |
| Revenue Per Employee | $1.14M |
| Profits Per Employee | $43,671 |
| Employee Count | 697 |
| Asset Turnover | 0.57 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $26.10 million in taxes.
| Income Tax | 26.10M |
| Effective Tax Rate | 46.16% |
Stock Price Statistics
The stock price has decreased by -50.43% in the last 52 weeks. The beta is 1.47, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -50.43% |
| 50-Day Moving Average | 2.20 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 56.11 |
| Average Volume (20 Days) | 1,292,465 |
Short Selling Information
The latest short interest is 8.32 million, so 2.43% of the outstanding shares have been sold short.
| Short Interest | 8.32M |
| Short Previous Month | 8.69M |
| Short % of Shares Out | 2.43% |
| Short % of Float | 8.73% |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $796.85 million and earned $30.44 million in profits. Earnings per share was $0.09.
| Revenue | 796.85M |
| Gross Profit | 739.26M |
| Operating Income | 106.20M |
| Pretax Income | 56.54M |
| Net Income | 30.44M |
| EBITDA | 122.31M |
| EBIT | 106.20M |
| Earnings Per Share (EPS) | $0.09 |
Balance Sheet
The company has $261.82 million in cash and $542.81 million in debt, giving a net cash position of -$280.99 million or -$0.82 per share.
| Cash & Cash Equivalents | 261.82M |
| Total Debt | 542.81M |
| Net Cash | -280.99M |
| Net Cash Per Share | -$0.82 |
| Equity (Book Value) | 616.26M |
| Book Value Per Share | 1.81 |
| Working Capital | 397.10M |
Cash Flow
In the last 12 months, operating cash flow was $167.90 million and capital expenditures -$3.52 million, giving a free cash flow of $164.38 million.
| Operating Cash Flow | 167.90M |
| Capital Expenditures | -3.52M |
| Depreciation & Amortization | 16.12M |
| Net Borrowing | -5.00M |
| Free Cash Flow | 164.38M |
| FCF Per Share | $0.48 |
Margins
Gross margin is 92.77%, with operating and profit margins of 13.33% and 3.82%.
| Gross Margin | 92.77% |
| Operating Margin | 13.33% |
| Pretax Margin | 7.10% |
| Profit Margin | 3.82% |
| EBITDA Margin | 15.35% |
| EBIT Margin | 13.33% |
| FCF Margin | 20.63% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 8.98% |
| Shareholder Yield | 8.98% |
| Earnings Yield | 3.83% |
| FCF Yield | 20.68% |
Analyst Forecast
The average price target for GoodRx Holdings is $3.66, which is 57.76% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.66 |
| Price Target Difference | 57.76% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 3.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 0.9 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.9 |
| Piotroski F-Score | 6 |